Interações medicamentosas
Nivolumab + Ponesimod
Gravidade: Moderada
Nivolumab and Ponesimod: moderate interaction.
Última atualização
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Resumo
Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
O que esta interação significa em palavras simples
Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nivolumab belongs to Oncology; Ponesimod belongs to Central Nervous System.
Por que acontece
Ponesimod sequesters lymphocytes in lymphoid tissue via S1P receptor modulation, which may counteract the T-cell activation sought with PD-1 blockade.
O que fazer
Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
O que perguntar ao farmacêutico
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para desbloquear a orientação completa de conduta para Nivolumab e Ponesimod, as notas adicionais, os detalhes da evidência e o verificador de interações para uma prescrição completa.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Experimente o Pro+ grátis por 7 dias na web. Sem cartão.
Outras interações de Nivolumab
- Nivolumab + Thalidomide Grave
- Dexamethasone-tobramycin + Nivolumab Moderada
- Dexamethasone + Nivolumab Moderada
- Efgartigimod / hyaluronidase sc + Nivolumab Moderada
- Efgartigimod alfa + Nivolumab Moderada
- Nivolumab + Rozanolixizumab Moderada
Outras interações de Ponesimod
- Fingolimod + Ponesimod Contraindicada
- Ponesimod + Siponimod Contraindicada
- Amiodarone + Ponesimod Grave
- Amisulpride + Ponesimod Grave
- Anagrelide + Ponesimod Grave
- Anti-thymocyte + Ponesimod Grave
Perguntas frequentes
Can I take Nivolumab with Ponesimod?
MediHelp rates the interaction as moderate. Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
How serious is the interaction between Nivolumab and Ponesimod?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
